Puliretgene Parvec

哌普锐基

Report date: 2025/11/11 17:42:44

Base Information

Drug NamePuliretgene Parvec
Drug Alias NameZVS-101-eZVS101e
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionCYP4V2 gene transference
TargetsCytochrome P450 4V2
Therapy Area/IndicationsBietti Crystalline DystrophyRetinal Dysplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Chinagene Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChigenovo Co LtdBeijing Chinagene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsBietti Crystalline DystrophyRetinal Dysplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A